Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CECerus Corporation logo

Cerus Corporation (CERS)

NASDAQ Global Market · Currency in USD
$2.33 ▲ +0.02 (+0.87%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.33 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.31
Open
$2.31
Day's Range
$2.28 – $2.36
52 Week Range
$1.38 – $3.47
Volume
1,913,778
Avg. Volume
2,295,768
Market Cap
$469.55M
Beta (5Y Monthly)
1.83
PE Ratio (TTM)
--
EPS (TTM)
-$0.03
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.00

Profile: Cerus Corporation

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
268
CEO
Vivek K. Jayaraman
Website
cerus.com

Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate -$0.01 · Revenue est. $63.25M
DateEst.Actual
Jul 30, 2026-$0.01-$0.01Beat
Apr 30, 2026-$0.03-$0.01Beat
Mar 2, 2026-$0.01-$0.01Beat
Nov 6, 2025-$0.02-$0.00Beat
Aug 5, 2025-$0.02-$0.03Miss
May 1, 2025-$0.05-$0.04Beat

Analyst view

Consensus price target
$4.00 ▲ +71.7%
Range $4.00 – $4.00
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Similar stocks

Get free alerts on CERS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.